Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal nocturnal hemoglobinuria in pediatric patients.

    ... (N = 1); and jaundice, hepatitis, and isolated thrombocytopenia (N = 1). Immunosuppressive therapy was the initial ...

    Research Article last updated 12/12/2011 - 10:07am.

  2. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... including dose modifications for neutropenia and thrombocytopenia , and venous thromboembolism prophylaxis, where applicable, ...

    Research Article last updated 11/16/2011 - 2:10pm.

  3. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... has shown promising results in the treatment of thrombocytopenia . However, determination of an optimal chemotherapeutic ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... Grade 3-4 anemia , neutropenia , and thrombocytopenia with AZA vs CCR were 13% vs 4%, 61% vs 17%, and 50% vs ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. How we treat lower risk myelodysplastic syndromes.

    ... agonists are under investigation in lower risk MDS with thrombocytopenia . Some patients, while remaining "lower risk" MDS, have ...

    Research Article last updated 05/14/2013 - 2:56pm.

  6. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... experienced hematologic side effects (25% grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia ). Our results ...

    Research Article last updated 06/15/2012 - 2:13pm.

  7. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria

    ... trials of eculizumab due to lack of transfusions or thrombocytopenia ; eight had at least a good partial response. ...

    Research Article last updated 11/05/2012 - 10:28am.

  8. Clinical effect of point mutations in myelodysplastic syndromes

    ... TP53, and NRAS were most strongly associated with severe thrombocytopenia (P<0.001 for all comparisons) and an increased proportion ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... was similar regardless of cellularity. Grade 3-4 thrombocytopenia and neutropenia occurred similarly in ...

    Research Article last updated 02/04/2014 - 1:32pm.

  10. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

    ... a dose of 60 mg/m(2) was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 9.5 and 30% of the ...

    Research Article last updated 10/11/2011 - 5:58pm.